Introduction
Prostate cancer (PC) is one of the most commonly diagnosed cancers with an annual estimated incidence of 220,800 in 2015 (American Cancer Society, 2015 . PC still remains the second leading cause of cancer mortality in men, claiming more than 26,000 lives in 2015 (Siegel, Miller, & Jemal, 2016) . It is projected that the number of years of potential life lost due to PC deaths will increase by 226.1% from 291,853 in 2004 to 951,753 in 2050 (Li & Ekwueme, 2010 . However, the early detection of PC has been associated with a reduction in mortality more so than any other malignancy (Sanda & Kaplan, 2009) . PC, usually diagnosed in its early stages, can be treated with various modalities. Risks and concern for adverse effects as a result of treatment of patients with low-risk PC has led to new approaches for disease screening and surveillance (Sanda & Kaplan, 2009) . Despite these advances, there remains little data about patient awareness of PC and the frequency of screening.
Men at greater risk for PC and mortality did report higher rates of screening. This was true particularly in Black men who have a 60% greater risk of PC and 130% greater risk of PC-related mortality as well in men with a family history who are two to five times more likely to develop PC (McDavid, Melnik, & Derderian, 2000) . Racial disparities in the treatment of PC have been demonstrated. One study reported that Hispanic and African American men were given less medical monitoring, a necessary element of "watchful waiting" (Shavers, Brown, & Klabunde, 2004) . Furthermore, these men had longer median times from diagnosis to medical monitoring or procedure than White men (Shavers et al., 2004) . This study was designed to describe the rates of self-reported PC screening and awareness in an unselected group of emergency department patients sampled from a suburban tertiary care center population that is similar to the greater U.S. population and identify disparities in awareness. In statistical analysis, continuous variables were described using means and categorical variables were described using percentages. Comparisons were performed using chi-square tests and t tests for categorical and continuous variables, respectively.
Results
There were 470 completed surveys. The mean age of participants was 48 years (SD = 18) of whom 361 (77%) identified as White. Other demographic information and associated comorbidities are listed in Table 1 . Of the men surveyed, 451 (96%) reported they had heard of PC. Three hundred and thirty-nine participants (72%) had heard of the DRE. Of all participants, 217 (46%) reported that they had had a DRE. Most participants, 420 (89%), had heard of a prostate exam. Half, 233, of the participants claimed to have had a prostate exam. Initially, participants were asked about the DRE in two different ways to weed out inconsistent surveys. However, it was quickly determined that this method only illustrated a difference in the use of nomenclature when speaking with patients. A total of 222 participants (47%) stated that they had heard of the prostate-specific antigen (PSA) test. Only 137 participants (29%) claimed to have ever had a PSA test. Despite the relatively high levels of awareness of PC and screening modalities, disparities were consistently identified among certain demographics, including men identifying as African American and Hispanic, as reported in Table 2 . Disparities in awareness were also seen among populations with certain comorbidities including coronary artery disease and hypertension as seen in Table 3 .
More than three quarters (355, 76%) of participants believed they were at average risk of developing PC in the next 5 years. Thirty-five men (7%) believed they were at high risk and the remainder of participants had not heard of PC or reported they did not know their risk. Three hundred and thirty-nine participants (72%) believed they were at average risk for developing PC in 10 years; 50 (11%) reported they were high risk. Three hundred and nineteen participants (68%) reported they were at average risk of developing PC in their lifetime; 78 (17%) believed they were at high risk for developing PC. Of all participants, 287 (61%) reported they were aware of different levels of risk for developing PC.
Men with a first-degree relative diagnosed with PC, and therefore at high risk, were significantly more likely to believe they were at high risk for developing PC in the next 5 years, 10 years, and over their lifetimes (p < .001). However, less than half of men (13 of 27, 48%), who reported a first-degree relative with PC, were aware that they were at high risk during their lifetime. Similarly, less than 15% of African American men (3 of 23, 13%) were aware that they were at high risk.
Discussion and Conclusions
While nearly half of men surveyed had heard of the PSA exam and a majority of men had heard of PC, the DRE, and the prostate exam, significant disparities in awareness of PC and screening modalities were observed. Hispanic men and men who did not complete high school were significantly less aware of PC and the PSA test. Surprisingly, men with hypertension, likely to have interactions with a primary care provider, were less likely to be aware of the DRE and PSA test. Likewise, men with coronary artery disease were less likely to be aware of the prostate exam and PSA test despite recent interaction with a primary care physician. African American men, a population identified with an increased risk for PC, were significantly less aware of the PSA test. Single and divorced men were also less aware of the DRE.
This study used a convenience sample of patients in the emergency department while Academic Associates were present. In addition, patients were excluded if they were in critical condition, had an altered mental status, or were unable to speak English. This selection engenders (106) 77 (84) 88 (96) 57 (62) Graduate/professional degree 100 (59) 84 (48) 95 (54) 68 (39) Note. PC = prostate cancer; DRE = digital rectal exam; PE = prostate exam; PSA = prostate-specific antigen test. Participants who responded "yes" to awareness are shown above and compared with those who responded "no" (which are not shown above).Statistically significant comparisons are bolded. Note. PC = prostate cancer; DRE = digital rectal exam; PE = prostate exam; PSA = prostate-specific antigen test; CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disorder. Participants who responded "yes" to awareness are shown above and compared with those who responded "no" (which are not shown above). Statistically significant comparisons are bolded.
bias and is a limitation of the study. In addition, questions were asked directly to the participant instead of using a written form and this is a limitation. Last, because many patients have primary care providers outside of the hospital system and electronic medical records, it is not possible to assess the correctness of patient recall and this is a limitation. Overall, a meaningful gap was identified in awareness of risk for PC in men at high risk, with an affected firstdegree relative. These disparities were demonstrated in a randomly selected population that closely models that of the United States. Most important, the men at greatest risk were least likely to be aware; as a result, there exists a significant opportunity for education and screening that may benefit this population of high-risk patients unaware of their risk. Further research should evaluate the potential opportunities for conversations between health care providers and patients in high-risk populations so that patients can make informed decisions about their screening and early interventions.
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